Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Amit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, Diana Rasoulouniriana, Asaf Madi, Chen Luxenburg, Jonathan Cohen, Krishnanand Padmanabhan, Noam Shomron, Guy Shapira, Annette Gleiberman, Roma Parikh, Carmit Levy, Meora Feinmesser, Dov Hershkovitz, Valentina Zemser-Werner, Oran Zlotnik, Sanne Kroon, Wolf Dietrich Hardt, Reno DebetsNathan Edward Reticker-Flynn, Peleg Rider, Yaron Carmi

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to clonal selection and immunoediting, comparisons of paired primary and relapsed tumors in melanoma and breast cancers indicate that they share the majority of clones. Here, we demonstrate in both mouse models and clinical human samples that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by T cells and chemotherapies. While the outer cells in this cell-in-cell formation are often killed by reactive T cells, the inner cells remain intact and disseminate into single tumor cells once T cells are no longer present. This formation is mediated predominantly by IFNγ-activated T cells, which subsequently induce phosphorylation of the transcription factors signal transducer and acti-vator of transcription 3 (STAT3) and early growth response-1 (EGR-1) in tumor cells. Indeed, inhib-iting these factors prior to immunotherapy significantly improves its therapeutic efficacy. Overall, this work highlights a currently insurmountable limitation of immunotherapy and reveals a previously unknown resistance mechanism which enables tumor cells to survive immune-mediated killing without altering their immunogenicity.

Original languageEnglish
Article numbere80315
JournaleLife
Volume11
DOIs
StatePublished - 2022

Funding

FundersFunder number
Faculty of Life Sciences
Fritz Thyssen Stiftung Yaron Carmi Israel Cancer Research Fund Yaron Carmi Israel Science Foundation Yaron Carmi Tel Aviv University
Tel Aviv University

    Fingerprint

    Dive into the research topics of 'Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy'. Together they form a unique fingerprint.

    Cite this